Physician profile
Michael J Biles
NPI 1033596622
$3,530.52
in general payments reported to CMS, 2019-2025
34 companies · $1,491 in 2025
The $1,491 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $250 · 2023: $890 · 2024: $900 · 2025: $1,491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,281.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,280.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $388.62 | 2023-2025 | Orgovyx, Gemtesa |
| Boston Scientific Corporation | $346.06 | 2023-2025 | Ams 700, Ams 800 Artificial Urinary Sphincter, Rezum Generator |
| Urogen Pharma, INC. | $313.85 | 2023-2025 | Jelmyto |
| Telix Pharmaceuticals | $231.60 | 2023-2025 | Illuccix |
| Olympus America INC. | $180.51 | 2022-2023 | Itind System |
| Ferring Pharmaceuticals INC. | $173.44 | 2024-2025 | Adstiladrin |
| Arcutis Biotherapeutics, INC. | $160.02 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $156.05 | 2023-2024 | |
| Pfizer INC. | $137.88 | 2023-2025 | |
| Verrica Pharmaceuticals INC. | $125.00 | 2023 | Ycanth |
| Urovant Sciences INC | $116.40 | 2022 | |
| Dendreon Pharmaceuticals LLC | $109.38 | 2024 | Provenge |
| Bioprotect Medical, INC. | $103.35 | 2025 | Bioprotect Balloon Implant System |
| Axonics, INC. | $97.34 | 2024 | Axonics |
| Baxter Healthcare | $94.54 | 2024 | Tisseel |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Immunitybio, INC. | $90.75 | 2025 | |
| Astellas Pharma US INC | $87.61 | 2022-2025 | Xtandi |
| Verity Pharmaceuticals INC. | $68.78 | 2023-2025 | Trelstar, Tlando |
| Astrazeneca Pharmaceuticals LP | $68.14 | 2023-2025 | Lynparza |
| Novartis Pharmaceuticals Corporation | $58.71 | 2024-2025 | |
| Innovation Technologies INC | $48.46 | 2022 | |
| Abbvie INC. | $46.15 | 2023-2024 | Botox |
| Endo USA, INC. | $41.25 | 2025 | Aveed, Xiaflex |
| Accord Healthcare, INC. | $39.04 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $38.37 | 2024-2025 | Keytruda |
| Janssen Biotech, INC. | $35.40 | 2025 | Erleada |
| Civco Medical Instruments | $31.67 | 2024 | |
| 180 Medical, INC. | $29.80 | 2022 | |
| Tolmar, INC. | $24.49 | 2025 | Jatenzo, Eligard |
| Progenics Pharmaceuticals, INC. | $21.83 | 2023 | Pylarify |
| Myovant Sciences INC. | $20.77 | 2022 | |
| Calyxo, INC. | $17.05 | 2025 | Cvac Aspiration System |
| Medtronic, INC. | $14.31 | 2023 | Interstim |
| Coloplast Corp | $13.90 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Biles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.